摘要

Since the first successful transfusion in 1818, Transfusion Medicine has evolved significantly. The advent of plasma fractionation and availability of recombinant products allowed for precision replacement therapy to treat many hematological conditions, such as hemophilia, thrombotic thrombocytopenic purpura, and hereditary angioedema. A deeper understanding of the pathophysiology underlying those conditions along with the development of safer monoclonal and bispecific antibodies is now offering safe and effective alternatives to the simple conventional approach of replacing a missing plasma protein. Many biologicals are already in wide clinical use in areas such as rheumatology, gastroenterology, and medical oncology. The introduction of novel therapeutic antibodies within the realm of Transfusion Medicine will likely reshape the field and challenge the role of local blood establishments as the gate-keepers of such therapies.
原文英語
頁(從 - 到)208-211
頁數4
期刊Transfusion and Apheresis Science
58
發行號2
DOIs
出版狀態已發佈 - 四月 1 2019

指紋

Transfusion Medicine
Antibodies
Bispecific Antibodies
Hereditary Angioedemas
Thrombotic Thrombocytopenic Purpura
Medical Oncology
Hemophilia A
Rheumatology
Gastroenterology
Blood Proteins
Therapeutics

ASJC Scopus subject areas

  • Hematology

引用此文

New monoclonal/bi-specific antibodies : Reshaping transfusion medicine beyond replacement. / Goubran, Hadi; Goubran, Mariam; Seghatchian, Jerard; Burnouf, Thierry.

於: Transfusion and Apheresis Science, 卷 58, 編號 2, 01.04.2019, p. 208-211.

研究成果: 雜誌貢獻回顧型文獻

Goubran, Hadi ; Goubran, Mariam ; Seghatchian, Jerard ; Burnouf, Thierry. / New monoclonal/bi-specific antibodies : Reshaping transfusion medicine beyond replacement. 於: Transfusion and Apheresis Science. 2019 ; 卷 58, 編號 2. 頁 208-211.
@article{3dbcc30a47154f2a980f428092e33a39,
title = "New monoclonal/bi-specific antibodies: Reshaping transfusion medicine beyond replacement",
abstract = "Since the first successful transfusion in 1818, Transfusion Medicine has evolved significantly. The advent of plasma fractionation and availability of recombinant products allowed for precision replacement therapy to treat many hematological conditions, such as hemophilia, thrombotic thrombocytopenic purpura, and hereditary angioedema. A deeper understanding of the pathophysiology underlying those conditions along with the development of safer monoclonal and bispecific antibodies is now offering safe and effective alternatives to the simple conventional approach of replacing a missing plasma protein. Many biologicals are already in wide clinical use in areas such as rheumatology, gastroenterology, and medical oncology. The introduction of novel therapeutic antibodies within the realm of Transfusion Medicine will likely reshape the field and challenge the role of local blood establishments as the gate-keepers of such therapies.",
keywords = "Bispecific antibodies, Monoclonal, Replacement, Transfusion",
author = "Hadi Goubran and Mariam Goubran and Jerard Seghatchian and Thierry Burnouf",
year = "2019",
month = "4",
day = "1",
doi = "10.1016/j.transci.2019.03.011",
language = "English",
volume = "58",
pages = "208--211",
journal = "Transfusion and Apheresis Science",
issn = "1473-0502",
publisher = "Elsevier Limited",
number = "2",

}

TY - JOUR

T1 - New monoclonal/bi-specific antibodies

T2 - Reshaping transfusion medicine beyond replacement

AU - Goubran, Hadi

AU - Goubran, Mariam

AU - Seghatchian, Jerard

AU - Burnouf, Thierry

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Since the first successful transfusion in 1818, Transfusion Medicine has evolved significantly. The advent of plasma fractionation and availability of recombinant products allowed for precision replacement therapy to treat many hematological conditions, such as hemophilia, thrombotic thrombocytopenic purpura, and hereditary angioedema. A deeper understanding of the pathophysiology underlying those conditions along with the development of safer monoclonal and bispecific antibodies is now offering safe and effective alternatives to the simple conventional approach of replacing a missing plasma protein. Many biologicals are already in wide clinical use in areas such as rheumatology, gastroenterology, and medical oncology. The introduction of novel therapeutic antibodies within the realm of Transfusion Medicine will likely reshape the field and challenge the role of local blood establishments as the gate-keepers of such therapies.

AB - Since the first successful transfusion in 1818, Transfusion Medicine has evolved significantly. The advent of plasma fractionation and availability of recombinant products allowed for precision replacement therapy to treat many hematological conditions, such as hemophilia, thrombotic thrombocytopenic purpura, and hereditary angioedema. A deeper understanding of the pathophysiology underlying those conditions along with the development of safer monoclonal and bispecific antibodies is now offering safe and effective alternatives to the simple conventional approach of replacing a missing plasma protein. Many biologicals are already in wide clinical use in areas such as rheumatology, gastroenterology, and medical oncology. The introduction of novel therapeutic antibodies within the realm of Transfusion Medicine will likely reshape the field and challenge the role of local blood establishments as the gate-keepers of such therapies.

KW - Bispecific antibodies

KW - Monoclonal

KW - Replacement

KW - Transfusion

UR - http://www.scopus.com/inward/record.url?scp=85063235120&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063235120&partnerID=8YFLogxK

U2 - 10.1016/j.transci.2019.03.011

DO - 10.1016/j.transci.2019.03.011

M3 - Review article

VL - 58

SP - 208

EP - 211

JO - Transfusion and Apheresis Science

JF - Transfusion and Apheresis Science

SN - 1473-0502

IS - 2

ER -